This is a 76-week trial comparing semaglutide 2.4 mg taken once weekly with liraglutide 3.0 mg taken once daily as an adjunct to a reduced-calorie diet and increased physical activity in subjects with overweight or obesity . This is a randomized, double-blinded trial. Each active medication will be compared against a placebo and be administered per a dosing schedule.
TARGET-HCC is a 5-year, longitudinal, observational study of the natural history and management of patients with HCC. The study will address important clinical questions that remain unanswered in the management of HCC with a unique research registry of participants with HCC from academic and community real-world practices. TARGET-HCC is disease focused, not drug specific, which allows for continuous acquisition of real-world evidence regarding the natural history, management, and outcomes of treatment with current therapies and new treatments that may be utilized in usual clinical practice.
This is a 5-year, longitudinal, observational study of patients with NAFL or NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.